Author:
Gjorgjievski Nikola,Karanfilovski Vlatko,Arsov Todor,Vidimliski Pavlina Dzekova,Andreevska Galisna Severeova,Selim Gjulshen,Dejanov Petar,Jordanova Vasilena,Marinova Ivelina,Paskalev Emil,Nikolov Igor G.
Abstract
IntroductionFabry disease is a rare X-linked lysosomal storage disorder caused by α-galactosidase A (α-Gal A) deficiency. Reduced or absent enzyme activity causes progressive lysosomal accumulation of globotriaosylceramide (Lyso-Gb3) in various cells throughout the body to trigger inflammation and fibrosis.Case descriptionWe present the first familial case of Fabry Disease in North Macedonia identified based on clinical manifestations and confirmed through enzyme, biomarker, and genetic tests. The index case in the family was a 45-year-old male undergoing hemodialysis therapy. He has had chronic burning uncontrolled limb pain since childhood, intermittent abdominal cramps, anhidrosis, and hypertension. The constellation of clinical presentations accompanied by similar symptoms in close family members prompted the enzyme, biomarker, and genetic analyses for Fabry disease. Genetic testing identified a known pathogenic GLA missense variant c.443G>A or p.(Ser148Asn) in the hemizygous state. Subsequent family studies allowed identification of another hemizygous male and five heterozygous female carriers affected by this X-linked disorder.ConclusionWe report identification of the first familial case of Fabry disease in North Macedonia and describe the phenotype associated with the Ser148Asn GLA variant. Greater awareness of this rare disease linked to continuous medical education is crucial for timely diagnosis and treatment.
Reference30 articles.
1. A case of “angeio‐keratoma.”;Anderson;Br. J. Dermatology,1898
2. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes;Ashton-Prolla;J. investigative Med.,2000
3. Fabry disease and its management: a literature analysis;Besekar;Cureus,2023
4. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document;Biegstraaten;Orphanet J. rare Dis.,2015
5. Fabry disease in Serbia: current status and future perspectives;Ćelić;Vojnosanit. Pregl.,2022